Chiasma

company

About

Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.

  • 51 - 100

Details

Last Funding Type
Series D
Last Funding Money Raised
$38.50M
Industries
Biopharma,Biotechnology,Therapeutics
Founded date
Jan 1, 2001
Number Of Employee
51 - 100
Operating Status
Active

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$152.50M
Chiasma has raised a total of $152.50M in funding over 2 rounds. Their latest funding was raised on Feb 27, 2015 from a Series E round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 27, 2015 Series E $70M 1 Detail
Jul 23, 2012 Series D $38.50M 1 Detail
Nov 15, 2006 Series C $44M 1 Detail
Jan 1, 2004 Series A 1 Innomed Ventures Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Chiasma is funded by 2 investors. Innomed Ventures and ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Innomed Ventures Yes Series A
ARCH Venture Partners Series E